Eli Lilly (LLY) Non-Current Debt (2009 - 2026)

Eli Lilly has reported Non-Current Debt for 18 years, with the latest figure at $39.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt rose 14.12% year-over-year to $39.4 billion; the trailing twelve-month figure through Mar 2026 stood at $39.4 billion (up 14.12% YoY), and the FY2025 full-year result was $40.9 billion, up 43.26% from the prior year.
• Non-Current Debt for Q1 2026 stood at $39.4 billion, down from $40.9 billion in the prior quarter.
• The five-year high for Non-Current Debt was $40.9 billion in Q3 2025, with the low at $14.1 billion in Q3 2022.
• Historically, Non-Current Debt has averaged $25.2 billion across 5 years, with a median of $23.7 billion in 2024.
• Annual changes were most pronounced in 2022 — Non-Current Debt decreased 8.88% — and 2024, when it jumped 62.05%.
• Eli Lilly's Non-Current Debt stood at $14.7 billion in 2022, then gained by 24.31% to $18.3 billion in 2023, then surged by 55.71% to $28.5 billion in 2024, then jumped by 43.26% to $40.9 billion in 2025, then decreased by 3.67% to $39.4 billion in 2026.
• The last three Non-Current Debt figures came in at $39.4 billion (Q1 2026), $40.9 billion (Q4 2025), and $40.9 billion (Q3 2025), per Business Quant data.